| P2093 | author name string | Yi Liu | |
| | Yongge Zhao | |
| | Kristin V Tarbell | |
| | Chie Hotta-Iwamura | |
| | William D Coley | |
| | Juan A Quiel | |
| | Charles Benck | |
| P2860 | cites work | A novel transcription factor, T-bet, directs Th1 lineage commitment | Q22253874 |
| | Chromogranin A is an autoantigen in type 1 diabetes | Q24605199 |
| | Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction | Q24650734 |
| | Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes | Q26770386 |
| | Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 |
| | Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice | Q30644510 |
| | FoxP3+ regulatory T cells promote influenza-specific Tfh responses by controlling IL-2 availability | Q33580878 |
| | Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects | Q33604570 |
| | CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells | Q33623556 |
| | Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity | Q33918375 |
| | IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells | Q34096577 |
| | Interleukin 2 signaling is required for CD4(+) regulatory T cell function | Q34527240 |
| | Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. | Q34553677 |
| | Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. | Q34621389 |
| | Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. | Q34636874 |
| | An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells | Q34682216 |
| | Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis | Q35159540 |
| | Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse | Q35288506 |
| | The Role of Dendritic Cell Subsets and Innate Immunity in the Pathogenesis of Type 1 Diabetes and Other Autoimmune Diseases | Q35739662 |
| | STAT5 is a potent negative regulator of TFH cell differentiation | Q35761809 |
| | The basis of distinctive IL-2- and IL-15-dependent signaling: weak CD122-dependent signaling favors CD8+ T central-memory cell survival but not T effector-memory cell development | Q35832534 |
| | Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. | Q36043724 |
| | DCIR2+ cDC2 DCs and Zbtb32 Restore CD4+ T-Cell Tolerance and Inhibit Diabetes | Q36104619 |
| | Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice | Q36228938 |
| | Transcription factor Foxp3 and its protein partners form a complex regulatory network | Q36250037 |
| | On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity | Q36370816 |
| | In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes | Q36399048 |
| | CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. | Q36399104 |
| | Specialized role of migratory dendritic cells in peripheral tolerance induction | Q36580331 |
| | Antigen-specific effector CD4 T lymphocytes school lamina propria dendritic cells to transfer innate tolerance | Q36920276 |
| | Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease | Q36940174 |
| | Interleukin-2 and regulatory T cells in graft-versus-host disease | Q37055805 |
| | Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease | Q37076418 |
| | Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment. | Q37098079 |
| | Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo | Q37312884 |
| | Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. | Q37418499 |
| | Regulatory T cell memory | Q37420611 |
| | CD8+ dendritic cell-mediated tolerance of autoreactive CD4+ T cells is deficient in NOD mice and can be corrected by blocking CD40L. | Q37496758 |
| | Etiology of type 1 diabetes | Q37735981 |
| | Antigen-specific immunotherapy of autoimmune and allergic diseases | Q37790023 |
| | Antigen presentation events in autoimmune diabetes. | Q37969489 |
| | IL-2 therapy in type 1 diabetes: "Trials" and tribulations | Q38090144 |
| | The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases | Q38424758 |
| | Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata | Q38429515 |
| | The Importance of Dendritic Cells in Maintaining Immune Tolerance. | Q39164401 |
| | Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. | Q40110921 |
| | Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells | Q41872700 |
| | Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions | Q41911767 |
| | IL-2R signaling is essential for functional maturation of regulatory T cells during thymic development | Q42006714 |
| | Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial | Q42232023 |
| | Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients | Q42472173 |
| | Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis | Q43048001 |
| | Murine pancreatic islet isolation | Q43189242 |
| | Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. | Q50759104 |
| | Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. | Q50940528 |
| | Selective stimulation of T cell subsets with antibody-cytokine immune complexes. | Q51984700 |
| | Lymph node T-cells do not optimally transfer diabetes in NOD mice | Q72616540 |
| | Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals | Q77704341 |
| | Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes | Q81690799 |
| | ICOS-dependent homeostasis and function of Foxp3+ regulatory T cells in islets of nonobese diabetic mice | Q83194001 |
| | A protocol for islet isolation from mouse pancreas | Q84817750 |
| P577 | publication date | 2018-02-10 | |
| P1433 | published in | Journal of Autoimmunity | Q15716783 |
| P1476 | title | Low CD25 on autoreactive Tregs impairs tolerance via low dose IL-2 and antigen delivery | |